Catabasis pursues bifunctional mutation-agnostic approach to DMD

February 9, 2017 Christoph Graener

Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified an NF-κB inhibitor—edasalonexent—as a potential Duchenne muscular dystrophy (DMD) treatment. Speaking at the 2017 Biotech Showcase, Dr. Jill Milne, co-founder, president and CEO of Catabasis, describes to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, the company’s ambitions to pursue a pivotal Phase III trial this year.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Jill C. Milne – President and CEO, Catabasis

Previous Article
PatientsLikeMe takes a holistic route to meet patient needs

Jamie Heywood, co-founder and chairman of PatientsLikeMe, spoke about the USD 100 million investment they r...

Next Article
Advancing neurokinin receptor antagonists in respiratory and women’s health

Starting the year with a cash injection of GDP 23 million, NeRRe Therapeutics intends to advance its neurok...